Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological Diseases
CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological, and immunological diseases.
| Ticker |
Sentiment |
Impact |
|
GOOG
|
Neutral
|
4 %
|
|
META
|
Neutral
|
4 %
|
|
BIIB
|
Somewhat Bullish
|
37 %
|
